Paul Jänicke

May 21, 2024 | chemistry-europe.onlinelibrary.wiley.com | Manuel Ricardo |Dayma Llanes |Robert C. Rennert |Paul Jänicke

Introduction Antibody-drug conjugates (ADCs)1 and peptide-drug conjugates (PDCs)2 are among the most promising chemotherapeutics for cancer treatment, mainly due to the ability of monoclonal antibodies (mAbs) and homing peptides to selectively deliver potent cytotoxic drugs into tumor cells.